Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.

Biotech SG&A Expenses: A Decade of Strategic Growth

__timestampMadrigal Pharmaceuticals, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014157460001244910
Thursday, January 1, 2015133920005029636
Friday, January 1, 201692900004846776
Sunday, January 1, 201776720005329003
Monday, January 1, 2018152930007121000
Tuesday, January 1, 2019226480009128000
Wednesday, January 1, 20202186400010731000
Friday, January 1, 20213731800010701000
Saturday, January 1, 20224813000016121000
Sunday, January 1, 202310814600037021000
Loading chart...

Unleashing the power of data

Navigating SG&A Expenses: A Tale of Two Biotech Firms

In the competitive world of biotechnology, effective cost management is crucial. This analysis of SG&A (Selling, General, and Administrative) expenses from 2014 to 2023 for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc. reveals intriguing trends. Madrigal Pharmaceuticals saw a staggering 587% increase in SG&A expenses, peaking at over $108 million in 2023. This surge reflects their aggressive expansion and investment in operational infrastructure. Meanwhile, Viking Therapeutics experienced a more modest 287% rise, reaching approximately $37 million in the same year. This suggests a more conservative growth strategy, focusing on sustainable scaling. The data highlights the contrasting approaches of these two companies in managing operational costs, offering valuable insights for investors and industry analysts. As the biotech sector continues to evolve, understanding these financial dynamics is key to predicting future market movements.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025